Emcure Pharmaceuticals Q1 FY27 Earnings Call: Semaglutide Gets NASH Clearance, International Revenue Grows 34%

Emcure Pharmaceuticals Ltd held its Q1 FY27 earnings call on August 06, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Financial Performance

• Revenue grew 22.8% YoY — to Rs.2,580 Cr in Q1 FY 2026-2027, driven by strong domestic and international performance across all regions.
• EBITDA rose 25.8% — to Rs.508 Cr with margin improving 50 bps to 19.7% in Q1 FY 2026-2027, supported by operating efficiencies.
• PAT grew 35.4% — to Rs.292 Cr in Q1 FY 2026-2027, with PAT margin expanding 110 bps year-on-year.
• Gross margin came in at 58.4% — in Q1 FY 2026-2027, declining YoY due to product mix shift and higher export share; management noted the quarter was closer to ~59%.
• R&D spend was Rs.90 Cr — representing 3.5% of revenue in Q1 FY 2026-2027, with management expecting spend to pick up in the remainder of the year to support full-year plans.

India Business Rebound and Growth Levers

• India revenue grew 10.2% YoY — to Rs.1,095 Cr in Q1 FY 2026-2027, with 12% sequential growth over Q4 FY 2025-2026, led by CNS, cardiology, and women's health therapies.
• Domestic organic growth (ex-Sanofi and Roche portfolios) was ~6-7% — in Q1 FY 2026-2027, impacted by consolidation at the Zaventis level; management described the India print as "clean" with no channel fill.
• Zuvantis restructuring is "substantially complete" — management stated the consolidation phase is over and the company is moving toward "acceleration" in FY 2026-2027, with focus shifting to growth.
• Management expects to grow in line with the industry from Q2 FY 2026-2027 — and faster than the industry in H2 FY 2026-2027, aided by a favorable base effect from H2 FY 2025-2026.
• Three levers outlined for domestic growth — making big brands bigger, in-licensing products from multinationals, and leveraging R&D-developed products (currently 30-35% of sales from R&D, including 11-12 Carrelis compounds).
• Povistra (Semaglutide) received clearance for NASH — in late July 2026; management believes the product will "emerge as a winner" given innovator association, strong data, and competitive pricing. Two major Indian players had a recall in the Semaglutide category, which management views as a potential advantage for Povistra.

Broad-Based Export Growth Across Regions

• International revenue grew 34.2% YoY — to Rs.1,485 Cr in Q1 FY 2026-2027, with constant currency growth of 12% and a forex impact of 6-7% (management cited ~12-13% forex impact on international revenue).
• Europe grew 32.8% to Rs.537 Cr — Canada 24.6% to Rs.427 Cr, and Rest of the World 44.8% to Rs.522 Cr in Q1 FY 2026-2027, with all regions contributing to the strong performance.
• ROW business grew 45% in Q1 FY 2026-2027 — led by the ARV (antiretroviral) segment which contributed 65% of ROW revenue; full-year FY 2026-2027 ARV share is expected at 50-55%, with the non-ARV segment also growing.
• M4 product has been introduced in all European countries — supplies are ramping up and orders are tender-based, so management expects uptake to increase in coming quarters.
• Semaglutide filing for Canada planned for Q2 FY 2026-2027 — the launch in Canada has been deferred, with possible relaunch in November 2026, dependent on supply from partner Dr. Reddy's; management noted the company is in the "second wave" for Semaglutide in Canada.

Margin Trajectory, Leverage, and Investment Profile

• Gross margin guidance revised to ~59% for FY 2026-2027 — from the earlier 60-61% range, owing to stronger-than-expected top-line performance (now expected at the higher end of low-to-mid-teens growth) and a higher mix of zero and ARV products with lower gross contribution but similar EBITDA accretion.
• Net debt stood at Rs.1,560 Cr in Q1 FY 2026-2027 — up from Q4 FY 2025-2026 due to higher working capital, which management says is now stabilized; expected to reduce to ~Rs.1,450 Cr by end of Q2 FY 2026-2027.
• Debt expected to increase further by Rs.250-Rs.500 Cr in Q2 FY 2026-2027 — to fund the acquisition of Mantra and the Denova minority stake, both completed in July 2026.
• R&D expense guidance for FY 2026-2027 maintained at 4-5% of revenue — management confirmed the full-year target despite Q1 spend of 3.5%, with investment expected to ramp up through the year.
• Management guided Emcure to become net cash by the end of FY 2027-2028 — a medium-term deleveraging target reflecting confidence in cash flow generation.

Leadership Transitions, Licensing, and Portfolio Expansion

• Chairman Berjis Desai to step down &